The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| REPL | -37.11% | -81.23% | -28.43% | -38% |
| S&P | +12.33% | +84.73% | +13.06% | +139% |
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks.
The biotech's recent meeting with FDA officials continued to resonate.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$1.64M | -82.2% |
| Market Cap | $327.05M | -56.3% |
| Market Cap / Employee | $0.68M | 0.0% |
| Employees | 479 | 44.7% |
| Net Income | -$83.10M | -56.6% |
| EBITDA | -$83.03M | -42.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $102.30M | -9.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $72.27M | 0.1% |
| Short Term Debt | $4.05M | 2.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -69.91% | -29.7% |
| Return On Invested Capital | -33.91% | -5.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$82.56M | -102.7% |
| Operating Free Cash Flow | -$81.21M | -110.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.17 | 1.56 | 1.72 | 0.97 | -44.85% |
| Price to Tangible Book Value | 2.17 | 1.56 | 1.72 | 0.97 | -44.85% |
| Enterprise Value to EBITDA | -8.42 | -4.35 | -5.87 | -1.66 | -80.81% |
| Return on Equity | -50.5% | -62.6% | -73.4% | -96.2% | 91.24% |
| Total Debt | $76.04M | $76.17M | $76.33M | $76.32M | 0.26% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
